Commentary
NSCLC Patients in Remission Have New Options for Maintenance Therapy
Jeffrey Kirshner: NSCLC Patients in Remission Have New Options for Maintenance Therapy
NSCLC Patients in Remission Have New Options for Maintenance Therapy
Dr. Kirshner is Partner and Director of Research, Hematology Oncology Associates of Central New York, East Syracuse; and Chief of Oncology, Community General Hospital, Syracuse. View profile. 1. In your view, which development in lung cancer that has occurred in 2009 could have the most significant impact on oncology?In my opinion, the top story in lung cancer for 2009 comes from new data about the role of maintenance therapy for patients whose non−small cell lung cancer is in remission. Two reports...